- |||||||||| Trial completion, Trial primary completion date: EoE(Eosinophilic Esophagitis) (clinicaltrials.gov) - Dec 16, 2016
P=N/A, N=10, Completed, Phase classification: P4 --> P1 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Apr 2016
- |||||||||| Trial primary completion date, Metastases: Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction (clinicaltrials.gov) - Dec 13, 2016
P2, N=96, Active, not recruiting, Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Mar 2014 --> Dec 2013
- |||||||||| bortezomib / Generic mfg., carboplatin / Generic mfg., paclitaxel / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction (clinicaltrials.gov) - Dec 13, 2016 P2, N=37, Completed, Trial primary completion date: Mar 2014 --> Dec 2013 Trial primary completion date: May 2008 --> Feb 2007
- |||||||||| bortezomib / Generic mfg., carboplatin / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Combination therapy, Metastases: Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction (clinicaltrials.gov) - Dec 12, 2016 P2, N=37, Completed, Completed --> Terminated; poor accrual Active, not recruiting --> Completed
- |||||||||| Trial completion, Enrollment change: Pillars4Life Trial (clinicaltrials.gov) - Dec 7, 2016
P=N/A, N=284, Completed, Trial primary completion date: Jan 2009 --> Jul 2005 Active, not recruiting --> Completed | N=400 --> 284
- |||||||||| Enrollment change, Trial termination: RELIEF Europe Study (clinicaltrials.gov) - Dec 6, 2016
P4, N=7, Terminated, Active, not recruiting --> Completed | N=400 --> 284 N=100 --> 7 | Recruiting --> Terminated; Insufficient enrollment
- |||||||||| 5-fluorouracil / Generic mfg., carboplatin / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Metastases: Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction (clinicaltrials.gov) - Dec 6, 2016 P2, N=56, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial primary completion date: Effects of Victoza (clinicaltrials.gov) - Dec 1, 2016 P1, N=72, Active, not recruiting, Not yet recruiting --> Completed Trial primary completion date: Oct 2016 --> Mar 2017
- |||||||||| Trial completion: CoFAR5: Eosinophilic Esophagitis Databank (clinicaltrials.gov) - Nov 14, 2016
P=N/A, N=709, Completed, Trial primary completion date: Sep 2016 --> Jan 2017 Active, not recruiting --> Completed
- |||||||||| Trial primary completion date: Optimizing (Breathing) Techniques for Radiotherapy of Esophageal and Lung Carcinomas (clinicaltrials.gov) - Nov 9, 2016
P=N/A, N=20, Recruiting, Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Oct 2016; Amgen decision following interim review of efficacy and safety data from the AMG 337 program. Trial primary completion date: Sep 2016 --> Dec 2016
- |||||||||| Trial primary completion date, Surgery: Prevention of Post-operative Pneumonia (POPP) (clinicaltrials.gov) - Oct 31, 2016
P2/3, N=330, Active, not recruiting, Recruiting --> Completed Trial primary completion date: Jun 2016 --> Jun 2017
- |||||||||| indomethacin / Generic mfg.
Trial primary completion date, Combination therapy: PIFA: Phase I Platinum Based Chemotherapy Plus Indomethacin (clinicaltrials.gov) - Oct 26, 2016 P1, N=18, Recruiting, Enrolling by invitation --> Completed | Trial primary completion date: Sep 2017 --> Jan 2016 Trial primary completion date: Feb 2016 --> Dec 2018
- |||||||||| Trial completion, Trial primary completion date: Cologne Esophageal Response Prediction Study (CERP-Study) (clinicaltrials.gov) - Oct 21, 2016
P=N/A, N=80, Completed, Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Apr 2015
- |||||||||| Trial completion, Trial primary completion date: Endoscopic Evaluation After Esophagectomy (clinicaltrials.gov) - Oct 18, 2016
P=N/A, N=10, Completed, N=124 --> 28 Recruiting --> Completed | Trial primary completion date: Nov 2018 --> Oct 2016
- |||||||||| cisplatin / Generic mfg.
Trial primary completion date, Biopsy: CHFR Methylation Status Esophageal Cancer Study (clinicaltrials.gov) - Oct 13, 2016 P2, N=56, Active, not recruiting, Recruiting --> Completed | Trial primary completion date: Nov 2018 --> Oct 2016 Trial primary completion date: Jun 2015 --> Jun 2014
|